Challenging Cases in Breast Cancer

Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty

Audio Highlights

Proceedings from a Satellite Symposium Held in Conjunction with the 2012 Oncology Nursing Society Annual Congress

Faculty
Georgia Litsas, MSN, ANP-BC, AOCNP
Joyce O’Shaughnessy, MD
Hope S Rugo, MD
G Lita Smith, RN, ACNP

Moderator
Neil Love, MD

From the publishers of:

Breast Cancer® UPDATE

Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/ONSBreast2012
Follow us at Facebook.com/ResearchToPractice Follow us on Twitter @DrNeilLove
Challenging Cases in Breast Cancer
Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty

OVERVIEW OF ACTIVITY
Breast cancer is one of the most rapidly evolving fields in oncology nursing. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, oncology nurses must be well informed of these advances and their associated efficacy benefits and related toxicities. This program provides nurses with access to the latest research developments in the systemic treatment of breast cancer and the perspectives of expert oncology nurses and clinical investigators regarding the application of this emerging research information to patient care. Upon completion of this CNE activity, oncology nurses, nurse practitioners and clinical nurse specialists should be able to formulate a more up-to-date and evidence-based approach to the care of patients with breast cancer.

LEARNING OBJECTIVES
• Use case-based learning to formulate individualized disease-management strategies for patients with breast cancer.
• Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of breast cancer, including endocrine agents, chemotherapy regimens and biologic treatments.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.
• Recall ongoing trials of investigational approaches in breast cancer, and refer patients and obtain consent for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by Research To Practice during the period of August 2012 through August 2013.

HOW TO USE THIS CNE ACTIVITY
This is an audio CNE program. This book contains CNE information, including learning objectives, faculty disclosures, a Post-test and an Educational Assessment and Credit Form. The corresponding website ResearchToPractice.com/ONSBreast2012 also includes links to relevant abstracts and full-text articles.

The Post-test and Educational Assessment and Credit Form may be completed in this book and either mailed to Research To Practice, One Biscayne Tower, 2 South Biscayne Blvd, Suite 3600, Miami, FL 33131 or faxed to (800) 447-4310. They may also be completed online. A statement of credit will be issued only upon receipt of a completed Post-test with a score of 75% or better and a completed Educational Assessment and Credit Form. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

This activity is supported by educational grants from Celgene Corporation, Eisai Inc and Genentech BioOncology.

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Smith had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms Litsas — Advisory Committee: Genentech BioOncology; Speakers Bureau: Celgene Corporation, Pfizer Inc. Dr O’Shaughnessy — Advisory Committee: Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Caris Diagnostics Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, GTx Inc, Johnson & Johnson Pharmaceuticals, Lilly USA LLC, Roche Laboratories Inc, Sanofi; Speakers Bureau: Bristol-Myers Squibb Company, Genentech Corporation, Sanofi. Dr Rugo — Paid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodexis Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
SELECT PUBLICATIONS


Blackwell K et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. *Proc ASCO* 2012;Abstract LBA1.


Rugo H et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). *Proc ASCO* 2012;Abstract CRA1002.


POST-TEST

**Challenging Cases in Breast Cancer: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty**

**QUESTIONS (PLEASE CIRCLE ANSWER):**

1. The mechanism of action of pertuzumab
   a. Is the same as that of trastuzumab
   b. Is distinct from that of trastuzumab because pertuzumab binds to the dimerization domain of HER2
   c. Allows for its use in combination with trastuzumab
   d. Both b and c

2. The Phase III randomized CLEOPATRA study demonstrated a statistically significant advantage in _______ with the addition of pertuzumab to trastuzumab and docetaxel in patients with metastatic breast cancer.
   a. Overall survival
   b. Progression-free survival
   c. Both a and b
   d. None of the above

3. T-DM1 is a novel agent that combines a maytansine derivative with ________.
   a. Docetaxel
   b. Trastuzumab
   c. Bevacizumab
   d. None of the above

4. Neutropenia is one of the most commonly occurring side effects associated with the chemotherapy drug eribulin.
   a. True
   b. False

5. A commonly reported side effect during treatment with T-DM1 is ________.
   a. Alopecia
   b. Nausea
   c. Transient thrombocytopenia
   d. Transient neuropathy

6. The results of a Phase II trial of T-DM1 versus trastuzumab and docetaxel for patients with untreated HER2-positive metastatic breast cancer demonstrated a significant difference in ________ in favor of T-DM1.
   a. Objective response rate
   b. Median progression-free survival
   c. Overall survival
   d. Both b and c

7. Benefits of nanoparticle albumin-bound (nab) paclitaxel include which of the following?
   a. Avoidance of corticosteroid premedications
   b. Shorter infusion time than standard paclitaxel
   c. Oral administration
   d. Both a and b

8. Which of the following toxicities can be associated with everolimus?
   a. Stomatitis
   b. Mucositis
   c. Interstitial pneumonitis
   d. All of the above
Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

**PART 1 — Please tell us about your experience with this educational activity**

How would you characterize your level of knowledge on the following topics?

<table>
<thead>
<tr>
<th>Topic</th>
<th>BEFORE</th>
<th>AFTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novel agents pertuzumab and T-DM1 for the treatment of HER2-positive metastatic breast cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Incorporation of the novel chemotherapy agents eribulin, nab paclitaxel and ixabepilone in the treatment of metastatic disease and the management of their side effects</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Emerging data with the mTOR inhibitor everolimus in combination with hormonal therapy for metastatic breast cancer: BOLERO-2 results</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Perspectives on hormone therapy in the treatment of male breast cancer</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

**Has the activity unfairly influenced you toward a particular product or service?**

☐ Yes  ☐ No

If yes, then describe what was presented:

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

Will this activity help you improve patient care?

☐ Yes  ☐ No  ☐ Not applicable

If yes, how will it help you improve patient care?

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

**Did the activity meet your educational needs and expectations?**

☐ Yes  ☐ No

If no, please explain:

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

**Please respond to the following learning objectives (LOs) by circling the appropriate selection:**

<table>
<thead>
<tr>
<th>LO</th>
<th>4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use case-based learning to formulate individualized disease-management strategies for patients with breast cancer.</td>
<td>4 3 2 1 N/M N/A</td>
</tr>
<tr>
<td>Discuss the benefits and risks associated with evidence-based systemic therapies used in the treatment of breast cancer, including endocrine agents, chemotherapy regimens and biologic treatments.</td>
<td>4 3 2 1 N/M N/A</td>
</tr>
<tr>
<td>Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with breast cancer.</td>
<td>4 3 2 1 N/M N/A</td>
</tr>
<tr>
<td>Recall ongoing trials of investigational approaches in breast cancer, and refer patients and obtain consent for study participation</td>
<td>4 3 2 1 N/M N/A</td>
</tr>
</tbody>
</table>
What other practice changes will you make or consider making as a result of this activity?

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

☐ Yes, I am willing to participate in a follow-up survey.
☐ No, I am not willing to participate in a follow-up survey.

PART 2 — Please tell us about the faculty and moderator for this educational activity

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Georgia Litsas, MSN, ANP-BC, AOCNP</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Joyce O'Shaughnessy, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>Hope S Rugo, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
<tr>
<td>G Lita Smith, RN, ACNP</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Moderator</th>
<th>Knowledge of subject matter</th>
<th>Effectiveness as an educator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neil Love, MD</td>
<td>4 3 2 1</td>
<td>4 3 2 1</td>
</tr>
</tbody>
</table>

Other comments about the faculty and moderator for this activity:

Please recommend additional faculty for future activities:

REQUEST FOR CREDIT — Please print clearly

Name: ................................................................. Specialty: .................................................................

Credentials: ☐ MD ☐ DO ☐ PharmD ☐ NP ☐ CNS ☐ RN ☐ PA ☐ Other .................................................................

Street Address: .................................................................................................................... Box/Suite: .................................................................

City, State, Zip: ....................................................................................................................

Telephone: .................................................................................................................... Fax: ....................................................................................................................

Email: ....................................................................................................................

Signature: .................................................................................................................... Date: .................................................................

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/ONSBreast2012/CNE.